E-LIB Suche - Ergebnisse für: Ribrag, V. (Vincent)

1

SAFETY PROFILE OF COMBINATION THERAPY WITH IMMUNE CHECKPOIN..:

Baldini, C. ; Romano, P.Martin ; Vincent, H....
Journal of Geriatric Oncology. 10 (2019) 6 - p. S108 , 2019

2

Cobimetinib Alone and Plus Venetoclax With/Without Atezoliz..:

Schjesvold, F.H. (Fredrik H.) ; Lourenco-Paiva, B.D. (Bruno David) ; Ribrag, V. (Vincent)...
https://pubmed.ncbi.nlm.nih.gov/36450626/. , 2023

Link: https://hdl.handle.net/1..

3

Histone deacetylase inhibitor abexinostat affects chromatin..:

Markozashvili, Diana ; Pichugin, Andrei ; Barat, Ana...
Gene. 580 (2016) 2 - p. 134-143 , 2016

Link: https://doi.org/10.1016/..

4

Treatment of older patients with mantle-cell lymphoma:

Kluin-Nelemans, J.C. (Hanneke) ; Hoster, E. (Eva) ; Hermine, O. (Olivier)...
http://repub.eur.nl/pub/69836. , 2012

Link: http://repub.eur.nl/pub/..

5

Molecular remission is an independent predictor of clinical..:

Pott, C. (Christiane) ; Hoster, E. (Eva) ; Delfau-Larue, M.H...
http://repub.eur.nl/pub/27431. , 2010

Link: http://repub.eur.nl/pub/..

6

Infections occurring following IL6 blockade for the managem..:

Valery, M. ; Saleh, K. ; Ecea, R....
Cancer Chemotherapy and Pharmacology. 92 (2023) 3 - p. 229-233 , 2023

Link: https://doi.org/10.1007/..

7

Incidence, characteristics, management and outcome of patie..:

Gueiderikh, A. ; Ung, M. ; Lazarovici, J....
Cancer/Radiothérapie. 27 (2023) 5 - p. 370-375 , 2023

Link: https://doi.org/10.1016/..

8

86P Validation of the Gustave Roussy Immune (GRIm) score in..:

Herbel, N. ; Goldschmidt, V. ; Michot, J-M....
ESMO Open. 8 (2023) 1 - p. 100944 , 2023

Link: https://doi.org/10.1016/..

9

LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE..:

Nastoupil, L. J. ; Kamdar, M. ; Chavez, J. C....
Hematological Oncology. 41 (2023) S2 - p. 212-214 , 2023

Link: https://doi.org/10.1002/..

10

PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIB..:

Hertzberg, M. ; Kalac, M. ; Cheah, C. Y....
Hematological Oncology. 41 (2023) S2 - p. 131-132 , 2023

Link: https://doi.org/10.1002/..

11

VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG ..:

Sarkozy, C. ; Thieblemont, C. ; Oberic, L....
Hematological Oncology. 41 (2023) S2 - p. 151-152 , 2023

Link: https://doi.org/10.1002/..

12

AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY..:

Kim, W. S. ; Shortt, J. ; Zinzani, P. L....
Hematological Oncology. 41 (2023) S2 - p. 195-196 , 2023

Link: https://doi.org/10.1002/..

13

Risks and benefits of phase 1 clinical trials for patients ..:

Michot, J. M. ; Guerra, M. ; Quivoron, C....
Hematological Oncology. 41 (2023) S2 - p. 600-601 , 2023

Link: https://doi.org/10.1002/..

14

A phase II, open‐label, multicenter study of capivasertib, ..:

Hodson, D. ; Shouse, G. ; Shin, H....
Hematological Oncology. 41 (2023) S2 - p. 562-564 , 2023

Link: https://doi.org/10.1002/..

15

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION ..:

Kuruvilla, J. ; Armand, P. ; Herrera, A. F....
HemaSphere. 6 (2022) - p. 1236-1237 , 2022

Link: https://doi.org/10.1097/..